A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Conclusions: LY3023414 has a tolerable safety profile and single agent activity in patients with advanced cancers. The RP2D of LY3023414 monotherapy is 200 mg BID based on safety, tolerability, and PK/Pharmacodynamic data.
PMID: 29636360 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 10, 2018 Category: Cancer & Oncology Authors: Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe ER, Fink A, Wacheck V, Moore KN Tags: Clin Cancer Res Source Type: research